Wednesday, February 10, 2010, 2:56pm SGT - The Singapore stock market closes in 2 hours and 4 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Santarus Inc. (SNTS)

At 5:00AM SGT: 3.70 USD  Down 0.01 (0.27%)  
 MORE ON SNTS 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Santarus, Inc. (NGM:SNTS) Delayed quote dataEdit
After Hours: 3.76 Up 0.06 (1.51%) as of 5:41am SGT on 02/10/10
Last Trade:3.70 USD
Trade Time:5:00AM SGT
Change:Down 0.01 (0.27%)
Prev Close:3.71
Open:3.70
Bid:3.13 x 100
Ask:4.27 x 100
1y Target Est:5.50
Day's Range:3.66 - 3.79
52wk Range:1.05 - 5.82
Volume:246,512
Avg Vol (3m):697,211
Market Cap:214.88M
P/E (ttm):N/A
EPS (ttm):-0.05
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add SNTS to Portfolio   Download Data

 HEADLINES 
•SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Tue, Feb 2)
•SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Sat, Jan 16)
•Neutral on Santarus
Zacks.com (Wed, Jan 6)
•Santarus Receives $20 Million
Zacks.com (Wed, Dec 30)
•Santarus eyes Phase III trials for diarrhea drug
at MarketWatch (Wed, Dec 30)
•Santarus Submits IND for Phase III Clinical Testing of Rifamycin SV MMX in Travelers' Diarrhea
Business Wire (Wed, Dec 30)
•3 Stocks Ready to Roar
at Motley Fool (Thu, Dec 24)
•Santarus Receives Previously Announced $20 Million Milestone for FDA Approval of ZEGERID OTC
Business Wire (Tue, Dec 22)
•Santarus Lippert/Heilshorn Life Sciences Call scheduled for 10:30 am ET today
Vcall (Tue, Dec 15)
•Santarus Announces Webcast Presentation at the Lippert/Heilshorn Life Sciences Virtual Conference
Business Wire (Tue, Dec 15)
•Santarus, JA Solar: Early Volume Plays
at TheStreet.com (Mon, Dec 7)
•SANTARUS INC Files SEC form 8-K, Other Events
EDGAR Online (Mon, Dec 7)
More Headlines for SNTS...
 ANALYST 
EPS Est (next year) (Dec-09) :0.33
EPS Est (in 2 years) (Dec-10) :0.28
Avg Rec (current)*:2.5
PEG Ratio:1.30
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Santarus, Inc., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that treat upper gastrointestinal diseases and disorders.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices